Navigation Links
Varian Medical Systems to Exhibit New TrueBeam™ System for Image-Guided Radiotherapy at ChinaMed Exhibition in Beijing
Date:3/21/2011

BEIJING, March 21, 2011 /PRNewswire/ -- Varian Medical Systems, Inc. (NYSE: VAR), the world's leading manufacturer of medical technology for treating cancer with radiotherapy, will showcase the company's new TrueBeam™ system for image-guided radiotherapy and radiosurgery at the 23rd International Medical Instruments and Equipment Exhibition in Beijing (ChinaMed), March 25-27, 2011.

TrueBeam was designed from the ground up to treat tumors with unprecedented speed and accuracy — including tumors that move during treatment as the patient breathes in and out.  Designed to advance the treatment of lung, breast, prostate, head and neck, and other types of cancer, TrueBeam features a multitude of technical innovations that dynamically synchronize imaging, patient positioning, motion management, and treatment delivery. With its High Intensity Mode, TrueBeam can deliver very high doses quickly and accurately, more than twice as fast as earlier generations of technology.

"The TrueBeam system was first introduced in the United States last April, and this will be the company's first time showing it to medical professionals in China," said Ling Zhang, business marketing manager for Varian Medical Systems.  "We are very excited about the opportunity to demonstrate the capabilities of this high-powered cancer fighting machine."

Varian will also highlight the company's X-ray products in the ChinaMed exhibit.  These include new technically advanced X-ray tubes and flat panel detectors developed to work together to improve image quality, increase throughput, and reduce the overall cost per procedure.  "With our expanded inventory and product support services in our Beijing facility, our customers will be able to take full advantage of the benefits of digital radiology," said Hsiao-Li Pan, manager of Varian's X-Ray Products business in China.

New Technology SeminarIn addition, Varian will officially introduce TrueBeam in China at a new technology seminar on the afternoon of March 25, 2011, in front of some sixty guests from the 25 top hospitals in China.  Speakers will include Joshua Lawson, M.D., radiation oncologist at the University of California, San Diego Medical Center, and Joseph Ting, PhD, chief medical physicist at the MIMA Cancer Center in Melbourne, Florida.  Dr. Lawson will speak about the clinical advantages of the TrueBeam system.  Dr. Ting's talk will focus on the system's High Intensity Mode, which significantly reduces treatment time, making it possible to treat some cancers that would not have been considered treatable before.

"Varian is pleased to showcase this new world-class solution at ChinaMed this year,” said Thomas P. Duffy, Varian's vice president of sales and marketing for the Asia Pacific region.  "Early adopters from around the world, like Dr. Lawson and Dr. Ting, are using TrueBeam to deliver precise image-guided treatments, providing cancer patients with access to highly personalized, advanced treatment options.”

ABOUT VARIAN MEDICAL SYSTEMSVarian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,400 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. The company's center in Beijing encompasses oncology equipment manufacturing operations, an educational center for radiotherapy clinical professionals, a customer service center, and X-ray Products assembly and service.  For more information, visit http://www.varian.com.FOR INFORMATION CONTACT:UNITED STATES

ASIAMeryl Ginsberg

Ling ZhangTel: 650.424.6444

Tel: +86-10-8785 8800meryl.ginsberg@varian.com

Cell: +86-139-1085 4745ling.zhang@varian.com
'/>"/>

SOURCE Varian Medical Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly ... it will present new data for galcanezumab and lasmiditan, ... of the International Headache Society (IHC) taking place Sept. ... Lilly will highlight new, long-term data from an ... doses of galcanezumab (120 mg and 240 mg) for ...
(Date:9/5/2017)... Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ... the development of oral drug delivery systems, announced today ... U.S. Food and Drug Administration (FDA) regarding ORMD-0801, the ... At the meeting, the FDA gave clear ... would be a Biologics License Application (BLA).  Such a ...
(Date:8/29/2017)... 2017 ivWatch, LLC, the leading provider of continuous monitoring ... has been awarded an Innovative Technology contract from Vizient, Inc., the ... ... in the early detection of peripheral IV infiltration and extravasation events ... The Innovative Technology contract was awarded to ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... “Finn Mouseson”: follows the ... in an average life. This mouse sets out on a journey that will show ... Mouseson” is the creation of newly published author and illustrator, Melody Gersonde-Mickelson, who has ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Psalms of Humidity”: is ... of mind and move the readers one step closer to God. “Psalms of Humidity” ... that his mistakes that have been made within his life are the very same ...
(Date:9/20/2017)... ... ... Sang At Her Funeral”: a tale of murder that will bring a church together ... Sang At Her Funeral” is the creation of published author, Annalise Harold, an IT ... twelve grandchildren. Before becoming a writer, Annalise had the opportunity to relocate often while ...
(Date:9/19/2017)... ... September 19, 2017 , ... Only a few physicians were ... Brevard’s own Ross A. Clevens, MD, FACS . The founder and medical director ... and Reconstructive Surgeon who trained at Yale, Harvard and the University of Michigan. He ...
(Date:9/19/2017)... ... 19, 2017 , ... Trusted debt-reduction firm CreditAssociates, LLC has announced two important ... excess of $835 million in resolved debt for its clients. , Credit card debt, ... the categories of debt settled by the company. With more than a decade of ...
Breaking Medicine News(10 mins):